Active Pharmaceutical Ingredient (API) >>LCZ696 Sacubitril Valsartan

LCZ696 (Sacubitril/Valsartan)

LCZ696 (sacubitril/valsartan) is a member of a new class of agents called angiotensin receptor-neprilysin inhibitors (ARNIs) which combine a neprilysin inhibitor and angiotensin receptor blocker (ARB). LCZ696 is currently indicated for treating patients with heart failure with reduced ejection fraction (HFrEF) in place of an angiotensin converting enzyme (ACE) inhibitor or ARB alone. 

LCZ696 is a mixture of valsartan and sacubitril in a 1:1 molar ratio. LCZ696 is a white powder consisting of thin hexagonal plates. It is stable in solid form as well as in aqueous (watery) solution with a pH of 5 to 7, and has a melting point of about 138 °C (280 °F).

CAS NO: 936623-90-4
MF: C48H55N6Na3O8
MW: 912.95500

Notice: If the compound involved in patent protection, do not use for commercial purposes, and only for the purpose of analysis and research experiments. If it’s sold to countries which constitute patent infringement, All the risks corresponding are unrelated to our company.

LCZ696 Sacubitril Valsartan

Stay connected with our social network